Management of Severe Ulcerative Colitis with Ambulatory Intravenous Corticosteroids (MOSAIC): A Treatment Approach to Avoid Hospitalization in Immunocompromised Patients.
This pilot study evaluates outpatient intravenous corticosteroids for acute severe ulcerative colitis, showing safety and satisfaction similar to hospitalization.
Key Points
Outpatient IV corticosteroid treatment is feasible and safe for patients with severe ulcerative colitis.
No patients required colectomy within 90 days, highlighting the effectiveness of outpatient management.
Thirty-day readmission rates were 30% for outpatients versus 40% for inpatients, indicating comparable outcomes.
Outpatient care showed similar clinical activity scores and patient satisfaction compared to inpatient care.